New Drug Development (NDD) business of MBC focuses mainly on clinical stage of drug development, of which MBC owns the rights for commercialization. The NDD team has substantial experience and track records in the development of new therapeutics, particularly in the area of oncology and liver diseases. The team is well positioned with professionals in medicine, life sciences, pharmacology, biometrics, regulatory affairs, and manufacturing. This composition assures that each project in the pipelines is efficiently managed in house side-by-side with the designated CRO for optimal quality. Due to MBC’s strength in protocol design, site selection, study execution and monitoring, and global regulatory submission, MBC is able to translate and validate innovative drug candidates into therapeutic opportunities for marketing authorization, thus unlocking the value of the projects within the pipeline.